With a focus on cutting-edge therapies, GenFleet Therapeutics is dedicated to serving significant unmet medical needs globally in oncology and immunology. Leveraging its deep understanding of disease biology and translational medicine, GenFleet has established a proprietary and fully integrated R&D system that yields a robust pipeline of multiple cutting-edge products with novel mechanisms and global IP.
Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates spanning small molecules and biologics. Its pipeline comprises numerous programs that have advanced to later-stage or pivotal clinical trials across China, the United States and Europe. Dupert® (fulzerasib) is the first approved KRAS G12C inhibitor in China and the third globally; it also received NDA priority review designation and two breakthrough therapy designations. Additionally, the first-line combination therapy of fulzerasib and cetuximab has progressed into phase II study in Europe, marking the world's first integration of KRAS and EGFR inhibitors for first-line non-small cell lung cancer treatment.
With proven success in developing RAS-pathway targeted therapies, GenFleet is also vigorously expanding its portfolio that includes other innovative therapies and novel modalities. Furthermore, it's strengthening its commercial collaborative network through strategic out-licensing agreements or clinical cooperations with prestigious listed companies across the world.
The Company actively implements the environmental, social, and governance requirements in all aspects, with its basic ESG obligations fulfilled as a publicly listed company. We have maintained good relationships with stakeholders of the Company, including government and regulatory authorities, shareholders and investors, customers, business partners, employees, and the public, adhering to principles of mutual benefit and consistently upholding our social responsibilities.
In an era of unprecedented innovation, the boom of innovative drug development will not only revolutionize the blueprint of the pharmaceutical industry at large, but also transform the health management plan of each individual in future. Adhering to the R&D of original products with global intellectual property rights, GenFleet strives to provide patients with accessible first-in-class therapies and to step further with the mission of delivering valuable healthcare solutions.
Robust R&D engine powered by cutting-edge innovation
From small molecules to a variety of advanced therapies, GenFleet's first-in-class pipeline always highlights the exploration of targets and indications without proof of concept while integrating a diversified portfolio of R&D models on the company's grand platform. Powered by scientific expertise and efficient execution, GenFleet aims to shape up a robust engine of novel drug development and a balanced matrix of industry-leading products.
Green operations and response to climate change
We incorporate the principles of green chemistry into the research, testing, and production processes for every product. The Company is committed to ensuring the safety of pharmaceutical raw materials, prioritizing atom economy in reaction design, and focusing on environmentally friendly outcomes. We continuously refine our processes and promote cutting-edge technologies such as enzyme catalysis and crystallization engineering. These efforts reduce the use of hazardous substances and the generation of waste, thereby fulfilling our commitment to environmental safety and public health. Our strict enforcement of the biological and chemical experiment system standards in the pharmaceutical industry, brings protection for the environment and employees’ physical and mental health, along with our green chemical design practices and experimental waste emission guidelines. In collaboration with multiple enterprises, we adopt a high-tech-driven, eco-friendly model to develop the “one center and three strengths” innovation hub in Zhangjiang Headquarters Park. We will continue to develop and optimize our energy management system, establish internal environmental risk assessment protocols, and implement wastewater and exhaust gas treatment systems. In doing so, we fulfill our social responsibility to conserve energy and reduce emissions.
Collaborative coexistence
One of our corporate values is “Collaborative Coexistence”: boosting efficiency with synergy, growing across boundaries. By collaborating across functions and roles, we aim to achieve business growth and ensure every employee’s development. The Company provides internal and external training to ensure employees enhance and refine their skill sets related to their work. To encourage skill enhancement and broaden career paths, each employee would be offered with open, fair, and impartial self-development opportunities and platforms based on his/her qualified performance and potential. The clear rank and promotion channels would be available for current employees while key ones shall attain targeted trainings.
-653.jpg)
